➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Express Scripts
Harvard Business School
McKesson

Last Updated: April 16, 2021

DrugPatentWatch Database Preview

BOTOX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Litigation for BOTOX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
In re: Aoki2013-07-30

See all BOTOX litigation

PTAB Litigation
PetitionerDate
2017-02-21

See all BOTOX litigation

Pharmacology for BOTOX

Company Disclosures: US Patents for BOTOX

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial The Regents of the University of Colorado (Boulder, CO) 2017-07-15 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for BOTOX

These patents were identified by searching patent claims

Supplementary Protection Certificates for BOTOX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB13/078 United Kingdom   Start Trial PRODUCT NAME: BOTULINUM TOXIN TYPE A; REGISTERED: FI 263103-5/2012 20130116; UK PL 00426/0118 - 0061 20130904; UK PL 00426/0074 - 0139 20130904; UK PL 00426/0119 - 0047 20130904
122008000043 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
132013902177250 Italy   Start Trial PRODUCT NAME: TOSSINA BOTULINICA DI TIPO A(BOTOX); AUTHORISATION NUMBER(S) AND DATE(S): NL25449, 20110826;034883013/M, 20130123
2013C/047 Belgium   Start Trial PRODUCT NAME: TOXINE BOTULIQUE TYPE A; AUTHORISATION NUMBER AND DATE: 263103-5/2012 20130128
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.